Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study

The use of modulator drugs that target the Cystic Fibrosis transmembrane conductance regulator (CFTR) is the final frontier in the treatment of Cystic Fibrosis (CF), a genetic multiorgan disease. F508del is the most common mutation causing defective formation and function of CFTR. Elexacaftor-tezaca...

Full description

Bibliographic Details
Main Authors: Giuseppe Migliorisi, Mirella Collura, Francesca Ficili, Tiziana Pensabene, Dafne Bongiorno, Antonina Collura, Francesca Di Bernardo, Stefania Stefani
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Pharmaceuticals
Subjects:
Cystic Fibrosis
elexacaftor-tezacaftor-ivacaftor
microbiology
airway colonization
Online Access:https://www.mdpi.com/1424-8247/15/5/606

Internet

https://www.mdpi.com/1424-8247/15/5/606

Similar Items